Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Schimrigk S, Brune N, Hellwig K, Lukas C, Bellenberg B, Rieks M, Hoffmann V, Pöhlau D, Przuntek H Eur J Neurol. 2006 Jun; 13(6):604-10. PMID: 16796584. Abstract CommentRecommendBookmarkWatch